FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2074748231> ?p ?o ?g. }

• W2074748231 endingPage "359" @default.
• W2074748231 startingPage "353" @default.
• W2074748231 abstract "Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy.BackgroundWe previously showed that chronic administration of an angiotensin converting enzyme (ACE) inhibitor to rats with passive Heymann nephritis (PHN), a model of membranous nephropathy with proteinuria and increased renal synthesis of endothelin-1 (ET-1), reduces urinary proteins and partially limits the exaggerated ET-1 renal synthesis. Here we compared the effect of an ETA receptor antagonist and an ACE-inhibitor given as single therapies with a combination of the two drugs in uninephrectomized PHN rats.MethodsPHN was induced with a single i.v. injection of rabbit anti-Fx1A antibody in 40 male Sprague Dawley rats. To accelerate the onset of renal damage rats underwent uninephrectomy seven days later and were subsequently treated until eight months with the ETA receptor antagonist LU-135252 (50 mg/kg b.i.d. p.o.) or the ACE-inhibitor trandolapril (1 mg/kg in the drinking water) or the combination of the two drugs.ResultsEither LU-135252 or trandolapril given alone prevented the increase in systolic blood pressure (SBP). Combined therapy was even more effective than single drugs. While LU-135252 and trandolapril reduced proteinuria by 23 to 25%, the drug combination resulted in 45% lowering of urinary proteins. Serum creatinine was significantly decreased by the combination, but not by the single drugs. Glomerulosclerosis and tubulointerstitial damage were more reduced by combined therapy than by LU-135252 or trandolapril alone.ConclusionsThese data suggest that contemporary blocking angiotensin II (Ang II) and ET-1 in an accelerated model of PHN had an additive renoprotective effect than single blocking Ang II or ET-1 and would represent a therapeutic advantage for renal disease patients who do not completely respond to ACE inhibitors. Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy. We previously showed that chronic administration of an angiotensin converting enzyme (ACE) inhibitor to rats with passive Heymann nephritis (PHN), a model of membranous nephropathy with proteinuria and increased renal synthesis of endothelin-1 (ET-1), reduces urinary proteins and partially limits the exaggerated ET-1 renal synthesis. Here we compared the effect of an ETA receptor antagonist and an ACE-inhibitor given as single therapies with a combination of the two drugs in uninephrectomized PHN rats. PHN was induced with a single i.v. injection of rabbit anti-Fx1A antibody in 40 male Sprague Dawley rats. To accelerate the onset of renal damage rats underwent uninephrectomy seven days later and were subsequently treated until eight months with the ETA receptor antagonist LU-135252 (50 mg/kg b.i.d. p.o.) or the ACE-inhibitor trandolapril (1 mg/kg in the drinking water) or the combination of the two drugs. Either LU-135252 or trandolapril given alone prevented the increase in systolic blood pressure (SBP). Combined therapy was even more effective than single drugs. While LU-135252 and trandolapril reduced proteinuria by 23 to 25%, the drug combination resulted in 45% lowering of urinary proteins. Serum creatinine was significantly decreased by the combination, but not by the single drugs. Glomerulosclerosis and tubulointerstitial damage were more reduced by combined therapy than by LU-135252 or trandolapril alone. These data suggest that contemporary blocking angiotensin II (Ang II) and ET-1 in an accelerated model of PHN had an additive renoprotective effect than single blocking Ang II or ET-1 and would represent a therapeutic advantage for renal disease patients who do not completely respond to ACE inhibitors." @default.
• W2074748231 created "2016-06-24" @default.
• W2074748231 creator A5001678867 @default.
• W2074748231 creator A5023556434 @default.
• W2074748231 creator A5031960025 @default.
• W2074748231 creator A5035442609 @default.
• W2074748231 creator A5090115261 @default.
• W2074748231 creator A5091449256 @default.
• W2074748231 date "1998-08-01" @default.
• W2074748231 modified "2023-09-27" @default.
• W2074748231 title "Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy" @default.
• W2074748231 cites W1909254787 @default.
• W2074748231 cites W1949417799 @default.
• W2074748231 cites W1964033455 @default.
• W2074748231 cites W1997180556 @default.
• W2074748231 cites W2003423004 @default.
• W2074748231 cites W2012497346 @default.
• W2074748231 cites W2018394477 @default.
• W2074748231 cites W2031534703 @default.
• W2074748231 cites W2033636526 @default.
• W2074748231 cites W2045434816 @default.
• W2074748231 cites W2058539576 @default.
• W2074748231 cites W2066895998 @default.
• W2074748231 cites W2067744739 @default.
• W2074748231 cites W2076584321 @default.
• W2074748231 cites W2077700858 @default.
• W2074748231 cites W2084138782 @default.
• W2074748231 cites W2108358727 @default.
• W2074748231 cites W2118643525 @default.
• W2074748231 cites W2119572224 @default.
• W2074748231 cites W2136898798 @default.
• W2074748231 cites W2145902340 @default.
• W2074748231 cites W2149496619 @default.
• W2074748231 cites W2615684303 @default.
• W2074748231 cites W4247166026 @default.
• W2074748231 doi "https://doi.org/10.1046/j.1523-1755.1998.00011.x" @default.
• W2074748231 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9690201" @default.
• W2074748231 hasPublicationYear "1998" @default.
• W2074748231 type Work @default.
• W2074748231 sameAs 2074748231 @default.
• W2074748231 citedByCount "77" @default.
• W2074748231 countsByYear W20747482312012 @default.
• W2074748231 countsByYear W20747482312014 @default.
• W2074748231 countsByYear W20747482312015 @default.
• W2074748231 countsByYear W20747482312016 @default.
• W2074748231 countsByYear W20747482312019 @default.
• W2074748231 countsByYear W20747482312020 @default.
• W2074748231 countsByYear W20747482312021 @default.
• W2074748231 countsByYear W20747482312023 @default.
• W2074748231 crossrefType "journal-article" @default.
• W2074748231 hasAuthorship W2074748231A5001678867 @default.
• W2074748231 hasAuthorship W2074748231A5023556434 @default.
• W2074748231 hasAuthorship W2074748231A5031960025 @default.
• W2074748231 hasAuthorship W2074748231A5035442609 @default.
• W2074748231 hasAuthorship W2074748231A5090115261 @default.
• W2074748231 hasAuthorship W2074748231A5091449256 @default.
• W2074748231 hasBestOaLocation W20747482311 @default.
• W2074748231 hasConcept C126322002 @default.
• W2074748231 hasConcept C134018914 @default.
• W2074748231 hasConcept C144980905 @default.
• W2074748231 hasConcept C170493617 @default.
• W2074748231 hasConcept C185592680 @default.
• W2074748231 hasConcept C27016395 @default.
• W2074748231 hasConcept C2775946357 @default.
• W2074748231 hasConcept C2776345702 @default.
• W2074748231 hasConcept C2777390665 @default.
• W2074748231 hasConcept C2778728240 @default.
• W2074748231 hasConcept C2779561371 @default.
• W2074748231 hasConcept C2779611605 @default.
• W2074748231 hasConcept C2780091579 @default.
• W2074748231 hasConcept C2780306776 @default.
• W2074748231 hasConcept C2781184683 @default.
• W2074748231 hasConcept C2908929049 @default.
• W2074748231 hasConcept C555293320 @default.
• W2074748231 hasConcept C71924100 @default.
• W2074748231 hasConcept C84393581 @default.
• W2074748231 hasConcept C98274493 @default.
• W2074748231 hasConceptScore W2074748231C126322002 @default.
• W2074748231 hasConceptScore W2074748231C134018914 @default.
• W2074748231 hasConceptScore W2074748231C144980905 @default.
• W2074748231 hasConceptScore W2074748231C170493617 @default.
• W2074748231 hasConceptScore W2074748231C185592680 @default.
• W2074748231 hasConceptScore W2074748231C27016395 @default.
• W2074748231 hasConceptScore W2074748231C2775946357 @default.
• W2074748231 hasConceptScore W2074748231C2776345702 @default.
• W2074748231 hasConceptScore W2074748231C2777390665 @default.
• W2074748231 hasConceptScore W2074748231C2778728240 @default.
• W2074748231 hasConceptScore W2074748231C2779561371 @default.
• W2074748231 hasConceptScore W2074748231C2779611605 @default.
• W2074748231 hasConceptScore W2074748231C2780091579 @default.
• W2074748231 hasConceptScore W2074748231C2780306776 @default.
• W2074748231 hasConceptScore W2074748231C2781184683 @default.
• W2074748231 hasConceptScore W2074748231C2908929049 @default.
• W2074748231 hasConceptScore W2074748231C555293320 @default.
• W2074748231 hasConceptScore W2074748231C71924100 @default.
• W2074748231 hasConceptScore W2074748231C84393581 @default.
• W2074748231 hasConceptScore W2074748231C98274493 @default.
• W2074748231 hasIssue "2" @default.

• next